In addition, a signature derived from CD8+ Trm cells predicts a favorable prognosis in HNSCC patients receiving ICI therapy, the molecular spectrum of which resembles that of T-E in breast cancer (BC) patients treated with a 1-cycle pembro (10). Here, CD8A is linked to breast cancer.